Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Working Capital Changes: 2015-2025

Historic Other Working Capital Changes for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to $438,000.

  • Cartesian Therapeutics' Other Working Capital Changes was N/A to $438,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of -$5.8 million for FY2024, which is 211.28% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Other Working Capital Changes stood at $438,000 for Q3 2025, which was up 162.04% from -$706,000 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Other Working Capital Changes high stood at $9.2 million for Q1 2023, and its period low was -$26.9 million during Q1 2022.
  • Over the past 3 years, Cartesian Therapeutics' median Other Working Capital Changes value was -$654,000 (recorded in 2023), while the average stood at $552,111.
  • In the last 5 years, Cartesian Therapeutics' Other Working Capital Changes tumbled by 4,572.13% in 2021 and then skyrocketed by 207.23% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Other Working Capital Changes (Quarterly) stood at -$17.1 million in 2021, then skyrocketed by 49.26% to -$8.7 million in 2022, then soared by 73.77% to -$2.3 million in 2023, then soared by 37.00% to -$412,000 in 2024, then crashed by 71.36% to $438,000 in 2025.
  • Its Other Working Capital Changes was $438,000 in Q3 2025, compared to -$706,000 in Q2 2025 and $5.8 million in Q1 2025.